These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17522277)

  • 1. Validation and reproducibility assessment of tigecycline MIC determinations by Etest.
    Bolmström A; Karlsson A; Engelhardt A; Ho P; Petersen PJ; Bradford PA; Jones CH
    J Clin Microbiol; 2007 Aug; 45(8):2474-9. PubMed ID: 17522277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method.
    Hope R; Parsons T; Mushtaq S; James D; Livermore DM
    J Antimicrob Chemother; 2007 Oct; 60(4):770-4. PubMed ID: 17704517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.
    Sader HS; Jones RN; Stilwell MG; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):181-6. PubMed ID: 16105562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility to tigecycline of isolates from samples collected in hospitalized patients with secondary peritonitis undergoing surgery.
    Tubau F; Liñares J; Rodríguez MD; Cercenado E; Aldea MJ; González-Romo F; Torroba L; Berdonces P; Plazas J; Aguilar L; Delgado A; García-Escribano N;
    Diagn Microbiol Infect Dis; 2010 Mar; 66(3):308-13. PubMed ID: 20022193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.
    Garrison MW; Mutters R; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
    Roveta S; Marchese A; Debbia EA
    Chemotherapy; 2008; 54(1):43-9. PubMed ID: 18073470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of Gram-positive cocci.
    Tsao SM; Lin HC; Lee CM; Hsu GJ; Chen CM; Sun W; Liu YC; Jang TN; Cheng YJ; Lu PL; Chiang PC; Wang LS; Kung HC; Chuang YC; Shi ZY; Liu JW; Huang CH; Lu CT; Liao CH; Hsueh PR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S184-7. PubMed ID: 19013352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiological MIC cut-off values for tigecycline calculated from Etest MIC values using normalized resistance interpretation.
    Kronvall G; Karlsson I; Walder M; Sörberg M; Nilsson LE
    J Antimicrob Chemother; 2006 Mar; 57(3):498-505. PubMed ID: 16410264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp.
    Casal M; Rodríguez F; Johnson B; Garduno E; Tubau F; de Lejarazu RO; Tenorio A; Giménez MJ; Bartolomé R; Garcia-Rey C; Aguilar L; García-Escribano N
    J Antimicrob Chemother; 2009 Jul; 64(1):69-72. PubMed ID: 19451133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study.
    Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; López F; Alvarez J; Picazo JJ;
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):437-44. PubMed ID: 16949245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
    Hoban DJ; Bouchillon SK; Johnson BM; Johnson JL; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):215-27. PubMed ID: 16105567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers.
    Gales AC; Sader HS; Fritsche TR
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):421-7. PubMed ID: 18068934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproducibility assessment of tigecycline MIC results by broth microdilution methods using commercially prepared dry-form panels.
    Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2005 May; 52(1):67-9. PubMed ID: 15878446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative activity of tigecycline and tetracycline on Gram-negative and Gram-positive bacteria revealed by a multicentre study in four North European countries.
    Nilsson LE; Frimodt-Møller N; Vaara M; Simonsen GS;
    Scand J Infect Dis; 2011 Sep; 43(9):707-13. PubMed ID: 21619494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Lu CT; Chuang YC; Sun W; Liu YC; Cheng YJ; Lu PL; Chen CM; Hsu GJ; Jang TN; Lee CM; Chiang PC; Shi ZY; Wang LS; Kung HC; Lin HC; Liao CH; Liu JW; Huang CH; Tsao SM; Hsueh PR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S179-83. PubMed ID: 19013351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of tigecycline and comparators against organisms associated with intra-abdominal infections collected as part of TEST (2004-2009).
    Mayne D; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2012 Oct; 74(2):151-7. PubMed ID: 22770774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007).
    Seifert H; Dowzicky MJ
    Chemotherapy; 2009; 55(4):241-52. PubMed ID: 19468222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
    Bouchillon SK; Iredell JR; Barkham T; Lee K; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tigecycline (GAR-936) activity against Streptococcus gallolyticus (bovis) and viridans group streptococci.
    Moet GJ; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):333-6. PubMed ID: 16989974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.